MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Rhythm Pharmaceuticals Inc

Fechado

SetorSaúde

86.68 -2.28

Visão Geral

Variação de preço das ações

24h

Atual

Mín

85.91

Máximo

89.59

Indicadores-chave

By Trading Economics

Rendimento

-6.2M

-49M

Vendas

-9.1M

33M

Margem de lucro

-151.352

Funcionários

283

EBITDA

-9.5M

-47M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+7.9% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

73M

4.1B

Abertura anterior

88.96

Fecho anterior

86.68

Sentimento de Notícias

By Acuity

46%

54%

157 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de jul. de 2025, 21:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Justice Department Won't Seek Injunction for T-Mobile Acquisition of U.S. Cellular

10 de jul. de 2025, 17:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Portugal Begins Process to Sell Stake in National Carrier -- Update

10 de jul. de 2025, 17:00 UTC

Grandes Movimentos do Mercado

K Wave Media Shares Drop After Convertible Note Agreement With Anson Funds

10 de jul. de 2025, 16:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Blackstone Makes $664 Million Counteroffer for Warehouse REIT Amid Bidding War -- 2nd Update

10 de jul. de 2025, 23:47 UTC

Conversa de Mercado

Gold Edges Higher Amid Lingering Global Trade Tensions -- Market Talk

10 de jul. de 2025, 23:40 UTC

Conversa de Mercado

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

10 de jul. de 2025, 22:36 UTC

Conversa de Mercado

Tourism Holdings' Profit Warning Less Concerning Than Others -- Market Talk

10 de jul. de 2025, 22:23 UTC

Conversa de Mercado

New Law Creates Winners and Losers Among Renewable-Energy Projects -- Market Talk

10 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

10 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

10 de jul. de 2025, 20:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Toyota Tsusho America Completes Acquisition of Radius Recycling

10 de jul. de 2025, 19:56 UTC

Conversa de Mercado

Gold Rises on Inflation Concerns -- Market Talk

10 de jul. de 2025, 19:33 UTC

Conversa de Mercado

Oil Snaps Winning Streak As Oversupply Concerns Return -- Market Talk

10 de jul. de 2025, 19:21 UTC

Conversa de Mercado

U.S. Natural Gas Rebound on Benign Storage Build -- Market Talk

10 de jul. de 2025, 18:46 UTC

Conversa de Mercado

Mexican Industrial Production Seen as Mixed in May -- Market Talk

10 de jul. de 2025, 18:15 UTC

Conversa de Mercado

Brazil's Bullish Outlook Expected to Survive Trump Tariffs -- Market Talk

10 de jul. de 2025, 18:03 UTC

Conversa de Mercado
Ganhos

Travel Agency Investors Cautiously Optimistic After Delta Report -- Market Talk

10 de jul. de 2025, 17:57 UTC

Conversa de Mercado

US Labor Shortage Could Weigh on Business, Economic Growth -- Market Talk

10 de jul. de 2025, 17:34 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Conagra Falls While Simply Good Foods Adapts. What's Eating Food Companies. -- Barrons.com

10 de jul. de 2025, 17:34 UTC

Conversa de Mercado

Canada Vows Fight Over Trump's Copper Tariffs -- Market Talk

10 de jul. de 2025, 17:20 UTC

Conversa de Mercado

Copper Climbs as Futures Wrangle With Trump Tariff -- Market Talk

10 de jul. de 2025, 17:20 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

10 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

10 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

10 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

10 de jul. de 2025, 16:02 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 de jul. de 2025, 16:02 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

10 de jul. de 2025, 16:02 UTC

Conversa de Mercado

Embraer Expected to Bear Brunt of U.S. Tariffs on Brazil -- Market Talk

10 de jul. de 2025, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Investor AB: Advanced Instruments' Acquisition of Nova Biomedical Completed

10 de jul. de 2025, 15:41 UTC

Conversa de Mercado

U.S. Natural Gas Storage Surplus Holds Steady -- Market Talk

Comparação entre Pares

Variação de preço

Rhythm Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

7.9% parte superior

Previsão para 12 meses

Média 96.07 USD  7.9%

Máximo 129 USD

Mínimo 69 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para Rhythm Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

15 ratings

14

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

60 / 65.58Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

157 / 376 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.